Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation

NCT02991781 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2020-02-17

No results posted yet for this study

Summary

This study will develop and experimentally test the efficiency of a neurofeedback training protocol vs. varenicline use for smoking cessation.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Smoking

Interventions

OTHER

Biofeedback and Neurofeedback Training

The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.

DRUG

Varenicline use for smoking cessation

The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.

OTHER

Sham Neurofeedback

Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.

OTHER

Passive Control

Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.

Sponsors & Collaborators

  • AAI Scientific Cultural Services Ltd (AAISCS)

    collaborator OTHER
  • NATIONAL ASSOCIATION OF GENERAL PRACTITIONERS IN BULGARIA

    collaborator UNKNOWN
  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Panos Bamidis, Ass. Prof · Medical School, Aristotle University of Thessaloniki

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Bulgaria
  • Cyprus
  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991781 on ClinicalTrials.gov